These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25898456)

  • 1. [Renal aspects of sodium glucose cotransporter 2 inhibitors].
    Beaud F; Pruijm M; Humbert A; Burnier M; Zanchi A
    Rev Med Suisse; 2015 Feb; 11(463):488-92. PubMed ID: 25898456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.
    Nair S; Wilding JP
    J Clin Endocrinol Metab; 2010 Jan; 95(1):34-42. PubMed ID: 19892839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic and renal implications of sodium-glucose cotransporter- 2 inhibitors in type 2 diabetes mellitus.
    Tejedor Jorge A
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():35-43. PubMed ID: 28760224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?
    Bertinat R; Nualart F; Yáñez AJ
    J Cell Physiol; 2016 Aug; 231(8):1635-7. PubMed ID: 26661279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
    Bakris GL; Fonseca VA; Sharma K; Wright EM
    Kidney Int; 2009 Jun; 75(12):1272-1277. PubMed ID: 19357717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update.
    Novikov A; Vallon V
    Curr Opin Nephrol Hypertens; 2016 Jan; 25(1):50-8. PubMed ID: 26575393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [SGLT2 inhibitor].
    Kubota N; Kadowaki T
    Nihon Rinsho; 2015 Dec; 73(12):2091-5. PubMed ID: 26666158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
    Škrtić M; Cherney DZ
    Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):96-103. PubMed ID: 25470017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
    Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
    Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
    Girard J
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
    Chrysant SG
    Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal glucose reabsorption inhibitors to treat diabetes.
    Bailey CJ
    Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renal effects of SGLT2 inhibitors and a mini-review of the literature.
    Andrianesis V; Glykofridi S; Doupis J
    Ther Adv Endocrinol Metab; 2016 Dec; 7(5-6):212-228. PubMed ID: 28203358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
    DeFronzo RA; Norton L; Abdul-Ghani M
    Nat Rev Nephrol; 2017 Jan; 13(1):11-26. PubMed ID: 27941935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects.
    de Leeuw AE; de Boer RA
    Eur Heart J Cardiovasc Pharmacother; 2016 Oct; 2(4):244-55. PubMed ID: 27533948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
    Santer R; Calado J
    Clin J Am Soc Nephrol; 2010 Jan; 5(1):133-41. PubMed ID: 19965550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.